Literature DB >> 35895154

Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma.

Peng Ma1, Chuanxin Zou1, Shitao Xia2.   

Abstract

The Notch pathway is a highly conserved signaling pathway involved in the regulation of cell proliferation and differentiation. However, the relationships between Notch pathway-related genes (NPRGs), immunosuppression, and immunotherapy resistance of hepatocellular carcinoma (HCC) remain unclear. Gene expression data and clinical information were extracted from GSE14520, GSE36376, GSE76427, LIRI-JP, TCGA-LIHC, GSE20140, GSE27150, and IMvigor210 datasets. A consensus clustering analysis based on 10 NPRGs was performed to determine the molecular subtypes, and then a notchScore was constructed based on differentially expressed and prognostic genes between molecular subtypes. Two molecular subgroups with significantly distinct survival and immune cell infiltration were identified. Then, a notchScore was constructed to quantify the Notch index of each patient with HCC. Next, we investigated the correlations between the clinical characteristics and the notchScore using logistic regression. Furthermore, multivariate Cox analysis showed that a high notchScore was an independent predictor of poor overall survival (OS) in the TCGA and LIRI-JP datasets and was associated with higher pathological stages. Additionally, a high notchScore was associated with higher immune cells, higher ESTIMATE score, higher immune score, higher stromal score, higher immune checkpoint, and lower tumor purity, which was consistent with the "immunity tidal model theory." Importantly, a high notchScore was sensitive to immunotherapy. Additionally, GSEA indicated that several GO and KEGG items associated with apoptosis, immune-related pathways, and cell cycle signal pathways were significantly enriched in the high notchScore phenotype pathway. Our findings propose that a high notchScore is a prognostic biomarker and correlates with immune infiltration and sensitivity to immunotherapy in HCC.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Hepatocellular carcinoma; Immunotherapy; Notch pathway-related genes; Scoring system; Tumor microenvironment

Year:  2022        PMID: 35895154     DOI: 10.1007/s00251-022-01273-6

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   3.330


  46 in total

1.  Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma.

Authors:  Soomin Ahn; Jiyeon Hyeon; Cheol-Keun Park
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2013-06

2.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

3.  Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression.

Authors:  Levi J Beverly; Dean W Felsher; Anthony J Capobianco
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

Review 4.  Cellular composition of the tumor microenvironment.

Authors:  Stephen M Ansell; Robert H Vonderheide
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

5.  Principal component analysis: a method for determining the essential dynamics of proteins.

Authors:  Charles C David; Donald J Jacobs
Journal:  Methods Mol Biol       Date:  2014

6.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

Authors:  Richard S Finn; Baek-Yeol Ryoo; Philippe Merle; Masatoshi Kudo; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Jennifer Knox; Bruno Daniele; Scot W Ebbinghaus; Erluo Chen; Abby B Siegel; Andrew X Zhu; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2019-12-02       Impact factor: 44.544

Review 7.  Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.

Authors:  Ann-Lii Cheng; Chiun Hsu; Stephen L Chan; Su-Pin Choo; Masatoshi Kudo
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

Review 8.  Cancer classification using the Immunoscore: a worldwide task force.

Authors:  Jérôme Galon; Franck Pagès; Francesco M Marincola; Helen K Angell; Magdalena Thurin; Alessandro Lugli; Inti Zlobec; Anne Berger; Carlo Bifulco; Gerardo Botti; Fabiana Tatangelo; Cedrik M Britten; Sebastian Kreiter; Lotfi Chouchane; Paolo Delrio; Hartmann Arndt; Martin Asslaber; Michele Maio; Giuseppe V Masucci; Martin Mihm; Fernando Vidal-Vanaclocha; James P Allison; Sacha Gnjatic; Leif Hakansson; Christoph Huber; Harpreet Singh-Jasuja; Christian Ottensmeier; Heinz Zwierzina; Luigi Laghi; Fabio Grizzi; Pamela S Ohashi; Patricia A Shaw; Blaise A Clarke; Bradly G Wouters; Yutaka Kawakami; Shoichi Hazama; Kiyotaka Okuno; Ena Wang; Jill O'Donnell-Tormey; Christine Lagorce; Graham Pawelec; Michael I Nishimura; Robert Hawkins; Réjean Lapointe; Andreas Lundqvist; Samir N Khleif; Shuji Ogino; Peter Gibbs; Paul Waring; Noriyuki Sato; Toshihiko Torigoe; Kyogo Itoh; Prabhu S Patel; Shilin N Shukla; Richard Palmqvist; Iris D Nagtegaal; Yili Wang; Corrado D'Arrigo; Scott Kopetz; Frank A Sinicrope; Giorgio Trinchieri; Thomas F Gajewski; Paolo A Ascierto; Bernard A Fox
Journal:  J Transl Med       Date:  2012-10-03       Impact factor: 5.531

Review 9.  Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Authors:  Michael M Boyiadzis; John M Kirkwood; John L Marshall; Colin C Pritchard; Nilofer S Azad; James L Gulley
Journal:  J Immunother Cancer       Date:  2018-05-14       Impact factor: 13.751

Review 10.  Quantifying tumor-infiltrating immune cells from transcriptomics data.

Authors:  Francesca Finotello; Zlatko Trajanoski
Journal:  Cancer Immunol Immunother       Date:  2018-03-14       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.